Dr. Hanna M. Saba, MD

Dr. Saba practices at Cancer Care Specialists of Central Illinois, S.C. in Decatur, Illinois.

Dr. Saba's NPI, 1720070386, was assigned on August 19, 2005. Dr. Saba holds Illinois license 036118085.

Dr. Saba's primary practice is Cancer Care Specialists of Central Illinois, S.C., at 210 W McKinley Ave, Decatur, IL 62526 in Macon County. The practice phone is (217) 876-6600.

Dr. Saba's primary practice is Cancer Care Specialists of Central Illinois, S.C. in Decatur, Illinois. Dr. Saba is also affiliated with Sarah Bush Lincoln Health Center. The medical group on file is Cancer Care Specialists of IL. Dmand AI also links Dr. Saba to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Saba practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Saba's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Saba's licenses on file in 2 states: Illinois and Arkansas.

CMS data shows 191,937 Medicare services from Dr. Saba across 79 procedure codes in 2024, for 601 Medicare patients. Medicare paid $2,242,446 for them. Every service was in an office.

CMS counts 601 Medicare patients who saw Dr. Saba in 2024. The largest group is 65 to 74, with 227 patients. 75% of them have high blood pressure, and 71% have high cholesterol. 19% are also on Medicaid. Their average risk score is 1.87, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Saba's median patient age at 74, with 58% women.

In 2024, Dr. Saba wrote 1,758 Medicare Part D claims for 217 patients. 78% of them were for generic drugs. CMS names the drug for 1,506 of them, across 42 drugs with 11 or more claims each, at $3,574,938 in total drug cost. In 2023, CMS named 1,464 claims across 47 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Saba for performance year 2024, reported as part of a group. Dr. Saba accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Saba as offering telehealth.

Dmand AI links 1 paper to Dr. Saba in 2014. Dr. Saba's most frequent co-authors are Shirish Madhav Gadgeel, MD and Mohammad Jahanzeb, MD.

CMS Open Payments shows 881 general payments to Dr. Saba from 67 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 94% of the total. Novartis Pharmaceuticals Corporation paid the most, $1,479.